CLGN
CollPlant Biotechnologies Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$3.64
+6.54%Year over year
Reported trailing growth
- Revenue
- -84.3%
- EBITDA
- +6.5%
- EBIT
- +11.1%
- EPS
- +15.6%
- Free cash flow
- +6.6%
- Operating cash flow
- +3.6%
Forward estimates
Based on analyst estimates
- Revenue
- +474.6%
- EBITDA
- +85.7%
- EPS
- +81.3%
Three-year CAGR
- Revenue
- +99.4%
- EBITDA
- +32.1%
- EBIT
- +33.4%
- Net income
- +30.8%
- EPS
- +35.2%
- Free cash flow
- +35.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026